Interventional radiology

Icahn School of Medicine at Mount Sinai Awarded $10.2 Million NIH Grant to Explore the Early Signs of Arrhythmic Mitral Valve Prolapse

Retrieved on: 
Tuesday, September 26, 2023
Pi, American Heart Association, National Heart, Lung, and Blood Institute, Pathology, Arrhythmia, Doctor of Philosophy, Associate, Bangladesh Technical Education Board, Interventional radiology, Magnetic resonance imaging, Mitral regurgitation, Patient, Risk, Heart, Disease, Inflammation, Sudden death, Heart failure, Principal investigator, Diagnosis, Research, Prolapse, Cardiac electrophysiology, Mitral valve, Biomedical engineering, Death, Cardiac arrest, Mitral valve prolapse, Echocardiography, Stroke, Mount Sinai, Assistant, Fibrosis, Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, Blood, PET, Shahid Gangalal National Heart Centre, Lung, MRI, Scientific Computing and Imaging Institute, Recurrence, Pharmaceutical industry, Medical device, Medical imaging, Radiology, MD, Medicine

NEW YORK, Sept. 26, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $10.2 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to investigate risk factors for malignant arrhythmias in mitral valve prolapse. This work aims to develop a better understanding of the condition and novel solutions to improve patient outcomes.

Key Points: 
  • The grant is a collaboration between four Icahn Mount Sinai specialties: Cardiac Electrophysiology, Cardiology, Cardiovascular Surgery, and the BioMedical Engineering and Imaging Institute (BMEII).
  • The grant is a collaboration between four Icahn Mount Sinai specialties: Cardiac Electrophysiology, Cardiology, Cardiovascular Surgery, and the BioMedical Engineering and Imaging Institute (BMEII).
  • In the United States, it is estimated that between 7 and 9 million people have mitral valve prolapse, the most common form of valve disease.
  • Mitral valve prolapse occurs when two flaps within the mitral valve don't close smoothly or evenly, but instead bulge (prolapse) upward into the left atrium when the heart contracts.

Rady Children's Appoints Rush Chewning, MD, as Medical Director, Pediatric Interventional Radiology

Retrieved on: 
Wednesday, September 20, 2023
University of California, San Diego, Boston Children's Hospital, Society, University, Senior, Johns Hopkins School of Medicine, SPIR, Radiology, Rady Children's Hospital, Quality of life, Robin, UCSD, Bumin Hospital Group of Indang Medical Foundation, Interventional radiology, Medical director, UC, Patient, MMM, Medical foundation, SAN, University of Washington School of Medicine, Gravity anomaly, Diagnosis, Hospital, Health, Thoracic outlet syndrome, Nursing, Dentistry, MD

"As a top pediatric hospital, it has been a longstanding goal for us to establish a dedicated Pediatric Interventional Radiology program to effectively meet pediatric patients' needs and bring our existing radiology department to new heights."

Key Points: 
  • "As a top pediatric hospital, it has been a longstanding goal for us to establish a dedicated Pediatric Interventional Radiology program to effectively meet pediatric patients' needs and bring our existing radiology department to new heights."
  • He served as the junior representative to the Society for Pediatric Interventional Radiology (SPIR) board for two years from 2020 to 2022, supporting junior faculty and trainees in their careers and promoting awareness of pediatric Interventional Radiology to residents and medical students.
  • "Pediatric Interventional Radiology has so much to offer, including the potential to significantly improve patients' quality of life.
  • He completed his radiology residency at the University of Washington, where he also completed a Vascular and Interventional Radiology fellowship before a second fellowship in Pediatric Vascular and Interventional Radiology at Boston Children's Hospital.

Canon Medical introduces Alphenix Sky 12 HD interventional system with the new 12”×12” High-Definition (Hi-Def) Detector

Retrieved on: 
Tuesday, September 12, 2023
HD, HD-PLC, IO, Interventional cardiology, Canon Medical Systems Corporation, Interventional radiology, Neuroradiology, Patient, Patient safety, Interventional oncology, Cardiology, Blood vessel, SVP, Medical imaging

Tustin California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Tustin, CA, USA, 12th of September 2023 – Continuing its focus on providing clinicians with clarity and precision during interventional procedures, Canon Medical Systems Corporation is introducing this technology for the Alphenix Sky 12 HD interventional system with our proprietary high-resolution HD 76 Hi-Def detector.

Key Points: 
  • Tustin California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Tustin, CA, USA, 12th of September 2023 – Continuing its focus on providing clinicians with clarity and precision during interventional procedures, Canon Medical Systems Corporation is introducing this technology for the Alphenix Sky 12 HD interventional system with our proprietary high-resolution HD 76 Hi-Def detector.
  • The new Alphenix Sky 12 HD with 12”×12” Hi-Def detector can help improve visualization during Interventional Cardiology (IC), Interventional Neurology (IN), Interventional Oncology (IO), and Interventional Radiology (IR), including pediatric procedures.
  • The Sky 12HD expands the Alphenix family by adding 12”x12” Hi-Def detector to its existing 12”x16” Hi-Def detector.
  • These options now provide clinicians the ideal size for their unique procedural needs, complimenting to the existing lineup of Alphenix Sky+, Alphenix 4D CT, Alphenix Biplane, and Alphenix Core+ systems.

Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board

Retrieved on: 
Thursday, August 10, 2023
SAB, Electroporation, Brain, University, Neoplasm, ZEUS robotic surgical system, Spine, Cryotherapy, Research, Sorbonne University, Doctor of Philosophy, Pain, MRI, Interventional radiology, MD, Faculty, Neuro, Robotics, University of Bordeaux, Medical imaging, Radiology

Professor Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine.

Key Points: 
  • Professor Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine.
  • Professor Cornelis received his MD in 2003 and completed his radiology training and his fellowship in 2008 and 2010, respectively, at the University of Bordeaux in France.
  • “The support and endorsement of a global leader such as Professor Cornelis is a vote of confidence and a great honor for the company.
  • Professor Cornelis joins a team of global leaders in their fields that are already serving as members of our SAB,” said Dr. Eyal Morag, Chief Medical Officer of Microbot Medical.

Partner Veterinary Emergency & Specialty Center Introduces Board Certified Veterinary Specialists to The Team for Summer 2023 Opening

Retrieved on: 
Thursday, July 27, 2023
Oncology, Communication, Spinal cord, Cancer, Quality of life, DSM-IV codes, Brain, MS, Interventional radiology, Animal, Partner, Patient, Dog, Internal medicine, Pet, Neurology, Climate, DVM, Cat, Veterinary medicine, Medical imaging, MD, Surgery

FREDERICK, Md., July 27, 2023 /PRNewswire-PRWeb/ -- Partner Veterinary Emergency & Specialty Center (PVESC) is pleased to introduce its team of board-certified veterinary specialists in Medical Oncology, Surgery, Neurology, and Internal Medicine to the team at the Frederick, MD, location this Summer. Located within the Frederick Crossing Shopping Plaza on Guilford Drive, these highly qualified doctors will provide exceptional veterinary specialty care for pets in the Frederick community.

Key Points: 
  • Partner Veterinary Emergency & Specialty Center (PVESC) is introducing a team of board-certified veterinary specialists in Medical Oncology, Surgery, Neurology, and Internal Medicine to their Frederick, MD location.
  • FREDERICK, Md., July 27, 2023 /PRNewswire-PRWeb/ -- Partner Veterinary Emergency & Specialty Center (PVESC) is pleased to introduce its team of board-certified veterinary specialists in Medical Oncology, Surgery, Neurology, and Internal Medicine to the team at the Frederick, MD, location this Summer.
  • Located within the Frederick Crossing Shopping Plaza on Guilford Drive, these highly qualified doctors will provide exceptional veterinary specialty care for pets in the Frederick community.
  • Stacy Walls, Partner Veterinary Emergency & Specialty Center, 301-514-8690, swalls@partnervesc.

Partner Veterinary Emergency & Specialty Center Introduces Board Certified Veterinary Specialists to The Team for Summer 2023 Opening

Retrieved on: 
Wednesday, July 26, 2023
Oncology, Communication, Spinal cord, Cancer, Quality of life, DSM-IV codes, Brain, MS, Interventional radiology, Animal, Partner, Patient, Dog, Internal medicine, Pet, Neurology, Climate, DVM, Cat, Veterinary medicine, Medical imaging, Dentistry, MD, Surgery

FREDERICK, Md., July 26, 2023 /PRNewswire-PRWeb/ -- Partner Veterinary Emergency & Specialty Center (PVESC) is pleased to introduce its team of board-certified veterinary specialists in Medical Oncology, Surgery, Neurology, and Internal Medicine to the team at the Frederick, MD, location this Summer. Located within the Frederick Crossing Shopping Plaza on Guilford Drive, these highly qualified doctors will provide exceptional veterinary specialty care for pets in the Frederick community.

Key Points: 
  • FREDERICK, Md., July 26, 2023 /PRNewswire-PRWeb/ -- Partner Veterinary Emergency & Specialty Center (PVESC) is pleased to introduce its team of board-certified veterinary specialists in Medical Oncology, Surgery, Neurology, and Internal Medicine to the team at the Frederick, MD, location this Summer.
  • Partner Veterinary Emergency & Specialty Care (PVESC) is a women-helmed business whose mission is to transform the veterinary profession.
  • "The opportunity to bring this level of veterinary specialty care to Frederick, MD is a dream come true."
  • - Christine Stafford, President, PVESC
    Stacy Walls, Partner Veterinary Emergency & Specialty Care, 301-514-8690, [email protected] , https://partnervesc.com/

Adventist HealthCare Opens Ambulatory Surgery Center at National Harbor

Retrieved on: 
Tuesday, July 11, 2023
Travel, Adventist HealthCare, Interventional cardiology, Ophthalmology, Interventional radiology, Obstetrics & Gynecology (journal), Aneurysm, Adventism, University of Maryland Baltimore Washington Medical Center, County, Ear, Behavior, National Harbor, Maryland, Stroke, General surgery, Blood pressure, Outpatient surgery, Ambulatory Surgery Center Association, AHC, Health, Nursing, Hospital, Gastroenterology

NATIONAL HARBOR, Md., July 11, 2023 /PRNewswire/ -- Adventist HealthCare recently opened its new state-of-the-art Ambulatory Surgery Center located at National Harbor.

Key Points: 
  • NATIONAL HARBOR, Md., July 11, 2023 /PRNewswire/ -- Adventist HealthCare recently opened its new state-of-the-art Ambulatory Surgery Center located at National Harbor.
  • "I'm excited to be a part of this push to improve care in the community," said Dr. Carlin Williams, Director of Vascular Surgery at Adventist HealthCare Fort Washington Medical Center and Vice President of the Adventist HealthCare Ambulatory Surgery Center Governing Board.
  • In addition, the center at National Harbor is equipped to practice a variety of specialties: Bariatric, Ear, Nose, and Throat, Gastroenterology, General Surgery, Interventional Cardiology, Interventional Radiology, Obstetrics/Gynecology, Ophthalmology, Orthopedic/Podiatry, Pain/Spine, Urology, and more.
  • The Ambulatory Surgery Center will serve as a link between nearby Adventist HealthCare Fort Washington Medical Center and its new primary care facility, located just minutes from each other.

RSNA: Researchers Develop Photon-counting CT Protocol to Evaluate Lung Function

Retrieved on: 
Tuesday, July 11, 2023
Photon, Linda, Society, Emphysema, Hannover Medical School, Education, Perfusion, OAK, Diagnosis, Research, Carbon, Radiological Society of North America, Ventilation, Lung, Chronic obstructive pulmonary disease, Interventional radiology, X-ray, Publishing, Radiation, Patient, RSNA, Health, Medical imaging, Medical device, Radiology, New York University

OAK BROOK, Ill., July 11, 2023  /PRNewswire-PRWeb/ -- New CT technology allows for a comprehensive, simultaneous evaluation of lung structure and function, something not possible with standard CT, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • However, CT studies of lung function and perfusion, or blood flow, require dedicated protocols that cannot be combined.
  • Researchers in Germany and the Netherlands developed a chest imaging protocol that yields information on structure and function of the lungs as a one-stop-shop procedure.
  • The researchers studied the protocol in 197 patients with clinically indicated CT for various known and unknown lung function impairment.
  • "We believe that the proposed protocol is generally valuable for diseases with known or unknown lung function impairment," Dr. Shin said.

Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board

Retrieved on: 
Tuesday, July 11, 2023
SAB, EASL, Radiation, Society, European Society of Radiology, ZEUS robotic surgical system, ESR, Diagnosis, Editorial board, Woman, Abdominal Radiology, CIRSE, ILCA, Gastrointestinal tract, Interventional radiology, MD, Circulatory system, Executive Committee, Cardiovascular and Interventional Radiological Society of Europe, Health, Medical imaging, Radiology, Liver

Dr. Bargellini is the latest expansion of Microbot’s global presence with highly esteemed medical experts in large addressable markets.

Key Points: 
  • Dr. Bargellini is the latest expansion of Microbot’s global presence with highly esteemed medical experts in large addressable markets.
  • Dr. Bargellini’s primary clinical and scientific focus is on oncologic imaging and interventional oncology, with reference to liver imaging and liver tumors’ loco-regional and systemic therapies.
  • “It is encouraging that leading interventional radiologists continue to join Microbot as it embarks on the steps towards the commercialization of the system,” commented Eyal Morag, MD, Chief Medical Officer.
  • She serves as reviewer of several national and international journals and is Member of the Editorial Board of European Radiology and Cardiovascular and Interventional Radiology journals.

Bayer initiates Phase III studies with investigational contrast agent gadoquatrane

Retrieved on: 
Tuesday, June 27, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Tissue, Central nervous system, Radiology, Cancer, Diagnosis, GBCA, MRI, Interventional radiology, Magnetic resonance imaging, Patient, Physician, Conditional sentence, Phase, Safety, Medical imaging, Bayer

Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane, an investigational extracellular macrocyclic gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI).

Key Points: 
  • Bayer, a global leader in radiology, has initiated the Phase III clinical development program called QUANTI, aiming to evaluate the safety and efficacy of gadoquatrane, an investigational extracellular macrocyclic gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI).
  • Gadoquatrane is a highly stable MRI contrast agent featuring high relaxivity being studied to evaluate the potential of a substantially lower gadolinium (Gd) dose for patients.1
    The QUANTI clinical development program encompasses two large multinational Phase III studies, QUANTI CNS (central nervous system) and QUANTI OBR (other body regions), as well as one pediatric study, all investigating gadoquatrane at a dose of 0.04mmol Gd/kg body weight (bw).
  • The completion of a successful development program would demonstrate the lowest gadolinium dose for an MRI contrast agent.
  • “In addition to this potentially novel contrast agent gadoquatrane, Bayer has new automated injection systems and AI-enabled solutions.”